医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ABEC Advances Single-Use Bioreactor Volumes to 6,000 Liters

2019年09月10日 PM11:52
このエントリーをはてなブックマークに追加


 

BETHLEHEM, Pa.

ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced the availability of Custom Single Run (CSR®) Bioreactors with working volumes up to 6,000L. The 6,000L volume increases ABEC’s industry-leading 4,000L volume while continuing to deliver performance comparable to stainless steel systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910005787/en/

ABEC Advances Single-Use Bioreactor Volumes to 6,000 Liters (Graphic: Business Wire)

ABEC Advances Single-Use Bioreactor Volumes to 6,000 Liters (Graphic: Business Wire)

ABEC remains the only supplier providing fully-customizable single-use bioreactors with large scale capacity. The 6,000L CSR Bioreactor increases cell culture capacity per unit of floorspace, resulting in significant savings in capital, facility, and disposables cost. CSR bioreactor geometries are aligned with decades of industry experience scaling in stainless steel, delivering equivalent power per volume while maintaining low shear mixing. Consistent with all CSR products, the material, instrument, and component supply chains remain fully-transparent and non-proprietary so that biopharmaceutical manufacturers have better control and flexibility to manage quality, cost, and regulatory compliance.

“We understand that our customers cannot compromise on scalability and cost of goods when realizing other single-use benefits such as multi-product flexibility,” said Scott Pickering, ABEC President and CEO. “In applications where single-use is preferred, with 6,000L CSR bioreactors, customers can now achieve even greater economies of scale for cell culture production.”

About ABEC

Since 1974, ABEC has been a leader in delivering integrated process solutions and services for manufacturing in the biopharmaceutical industry. A majority of the world’s pharmaceutical and biotech companies are ABEC customers with many of today’s leading therapies manufactured by processes and equipment engineered, manufactured, installed and serviced by ABEC. ABEC’s unique value is based on long experience, complete in-house capabilities, a customized, flexible approach, and long-term credibility. Whether adding capacity or improving existing facilities ABEC’s turn-key solutions and support services reduce overall cost and time to market while delivering maximum productivity. www.abec.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005787/en/

CONTACT

Media Contact:

ABEC

Susan Cooper Curcio

+1 (610) 861 4666

scurcio@abec.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Dr. Reddy’s Laboratories announces launch of Doxercalciferol Injection in the U.S. Market
  • 海外の専門家によれば、リヤドは持続可能な都市への道を進んでいる
  • Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress
  • Zymeworks在ESMO亚洲大会上宣布推进与百济神州的临床合作并公布ZW25用于治疗HER2呈阳性癌症患者的1期临床研究更新数据
  •  Phenomics Health Inc. 收购专利药物代谢组技术